Featured Research

from universities, journals, and other organizations

Suppressing tumors by pulling the plug on glycolysis

Date:
February 24, 2014
Source:
The Rockefeller University Press
Summary:
Cancer cells have long been known to have higher rates of the energy-generating metabolic pathway known as glycolysis. This enhanced glycolysis is thought to allow cancer cells to survive the oxygen-deficient conditions they experience in the center of solid tumors. Researchers reveal how damaged cells normally switch off glycolysis as they shut down and show that defects in this process may contribute to the early stages of tumor development.

Mouse cells fail to thrive in suspension cultures when wild-type Mdm2 is expressed (left), but expression of a mutant form of Mdm2 (right), in combination with PGAM and an oncogenic protein called Ras, enhances glycolysis and promotes cell transformation (right).
Credit: Mikawa et al., 2014

Cancer cells have long been known to have higher rates of the energy-generating metabolic pathway known as glycolysis. This enhanced glycolysis, a phenomenon known as the Warburg effect, is thought to allow cancer cells to survive the oxygen-deficient conditions they experience in the center of solid tumors. A study in The Journal of Cell Biology reveals how damaged cells normally switch off glycolysis as they shut down and shows that defects in this process may contribute to the early stages of tumor development.

Various stresses can cause cells to cease proliferating and enter an inactive state known as "senescence" that prevents their transformation into tumor cells. In 2005, Hiroshi Kondoh and colleagues found that cells normally limit glycolysis as they enter senescence and that increasing the levels of the glycolytic enzyme PGAM can prevent cells from exiting the cell cycle. PGAM is increased in many tumors, stimulating glycolysis and other important pathways. But how cells regulate PGAM has been unclear.

Working at Kyoto University in Japan, Kondoh and colleagues followed up on their previous work and found that, in response to DNA damage or oncogene expression, PGAM was degraded, thereby inhibiting glycolysis as the cells entered senescence. The enzyme Mdm2 targeted PGAM for degradation in response to these senescence-inducing stresses.

"Mdm2 can clearly, in some cases, act as a tumor suppressor by destabilizing PGAM," says Kondoh. Recent studies have emphasized the importance of PGAM as a therapeutic target for cancer management. Identifying the modulators of PGAM stability might open up new avenues for intervention.


Story Source:

The above story is based on materials provided by The Rockefeller University Press. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. Mikawa, T. Maruyama, K. Okamoto, H. Nakagama, M. E. Lleonart, T. Tsusaka, K. Hori, I. Murakami, T. Izumi, A. Takaori-Kondo, M. Yokode, G. Peters, D. Beach, H. Kondoh. Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2. The Journal of Cell Biology, 2014; DOI: 10.1083/jcb.201306149

Cite This Page:

The Rockefeller University Press. "Suppressing tumors by pulling the plug on glycolysis." ScienceDaily. ScienceDaily, 24 February 2014. <www.sciencedaily.com/releases/2014/02/140224123634.htm>.
The Rockefeller University Press. (2014, February 24). Suppressing tumors by pulling the plug on glycolysis. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/02/140224123634.htm
The Rockefeller University Press. "Suppressing tumors by pulling the plug on glycolysis." ScienceDaily. www.sciencedaily.com/releases/2014/02/140224123634.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins